Cargando…
Passive Aβ Immunotherapy: Current Achievements and Future Perspectives
Passive immunotherapy has emerged as a very promising approach for the treatment of Alzheimer’s disease and other neurodegenerative disorders, which are characterized by the misfolding and deposition of amyloid peptides. On the basis of the amyloid hypothesis, the majority of antibodies in clinical...
Autores principales: | Schilling, Stephan, Rahfeld, Jens-Ulrich, Lues, Inge, Lemere, Cynthia A. |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
MDPI
2018
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6099643/ https://www.ncbi.nlm.nih.gov/pubmed/29751505 http://dx.doi.org/10.3390/molecules23051068 |
Ejemplares similares
-
Development of the clinical candidate PBD-C06, a humanized pGlu3-Aβ-specific antibody against Alzheimer’s disease with reduced complement activation
por: Hettmann, Thore, et al.
Publicado: (2020) -
Combination of the Glutaminyl Cyclase Inhibitor PQ912 (Varoglutamstat) and the Murine Monoclonal Antibody PBD-C06 (m6) Shows Additive Effects on Brain Aβ Pathology in Transgenic Mice
por: Hoffmann, Torsten, et al.
Publicado: (2021) -
Effector function of anti-pyroglutamate-3 Aβ antibodies affects cognitive benefit, glial activation and amyloid clearance in Alzheimer’s-like mice
por: Crehan, Helen, et al.
Publicado: (2020) -
Immunotherapy in colorectal cancer: current achievements and future perspective
por: Fan, Ahui, et al.
Publicado: (2021) -
Passive Immunization against Pyroglutamate-3 Amyloid-β Reduces Plaque Burden in Alzheimer-Like Transgenic Mice: A Pilot Study
por: Frost, Jeffrey L., et al.
Publicado: (2012)